Skip to main content
Premium Trial:

Request an Annual Quote

Avance Biosciences Licenses Gene Editing Off-Target Analysis Method From SeQure Dx

NEW YORK – Avance Biosciences said on Thursday that it has signed a licensing agreement with SeQure Dx for that firm's next-generation sequencing-based gene editing off-target analysis technology, GUIDE-seq.

Financial terms of the agreement were not disclosed.

GUIDE-seq, originally developed by Keith Joung's group at Massachusetts General Hospital and exclusively licensed by SeQure, is designed to assess the efficacy of genome editing tools such as CRISPR-Cas9.

Houston-based Avance said the licensing agreement would allow the company to support its clients' CRISPR-based therapeutic programs by offering a comprehensive gene editing on- and off-target analysis pipeline.

"We believe that this agreement will enable us to further expand our portfolio of NGS services that aid in the biological drug development process, especially for cell-based therapies utilizing CRISPR technologies,” Avance Cofounder and CEO Xuening Huang said in a statement.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.